These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7231393)

  • 21. Comparison of DNA damage by methylmelamines and formaldehyde.
    Ross WE; McMillan DR; Ross CF
    J Natl Cancer Inst; 1981 Jul; 67(1):217-21. PubMed ID: 6788992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cytotoxic action of 1,3,5-triazabicyclo[3.1.0]hexane-2,4-diones and 1,3,5-triazine-4,6-(1 H,5 H)-diones in murine and human tumor cells.
    Hall IH; Taylor K; Izydore RA; Coleman DE; Mitchell JA; Cummings R
    Pharmazie; 1998 Jun; 53(6):398-405. PubMed ID: 9675770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of the inhibition of DNA biosynthesis by 4,4'-diacetyldiphenylurea-bis(guanylhydrazone) in leukemia L1210 cells.
    Dave C; Ehrke J; Mihich E
    Cancer Res; 1973 Sep; 33(9):2129-34. PubMed ID: 4737638
    [No Abstract]   [Full Text] [Related]  

  • 24. Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.
    Draeger U; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):423-7. PubMed ID: 1277217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA alkali-labile sites induced by incorporation of 5-aza-2'-deoxycytidine into DNA of mouse leukemia L1210 cells.
    D'Incalci M; Covey JM; Zaharko DS; Kohn KW
    Cancer Res; 1985 Jul; 45(7):3197-202. PubMed ID: 2408746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigenicity of L1210 leukemic sublines induced by drugs.
    Nicolin A; Vadlamudi S; Goldin A
    Cancer Res; 1972 Apr; 32(4):653-7. PubMed ID: 5014777
    [No Abstract]   [Full Text] [Related]  

  • 27. [The effect of benzylpenicillin and doxycycline on toxicity and antineoplastic action of cyclophosphamide and methotrexate in mice].
    Pakulska W
    Acta Pol Pharm; 1992; 49(1-2):35-40. PubMed ID: 8769079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide- or ifosfamide-treated L 1210 leukaemia cells: immunogenicity, viability and metabolism.
    Skórski T; Kawalec M; Hoser G
    Folia Biol (Praha); 1986; 32(5):354-65. PubMed ID: 3506526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of reactive metabolite-analogues of cyclophosphamide for comparisons of NMR kinetic parameters and anticancer screening data.
    Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
    Drugs Exp Clin Res; 1986; 12(6-7):527-32. PubMed ID: 3743371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of benzohydroxamic acids on L1210 lymphoid leukemia cell nucleic acid metabolism.
    Hall IH; Taylor K; Izydore RA; Daniels DL
    Pharmazie; 1998 Nov; 53(11):794-9. PubMed ID: 9853360
    [No Abstract]   [Full Text] [Related]  

  • 31. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
    Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cytotoxic action of iphosphamide and cyclophosphamide.
    Phelan ET; Vietti TJ; Valeriote FA; Coulter D
    Anticancer Res; 1981; 1(3):149-54. PubMed ID: 7342853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane.
    Li Y; Eiseman JL; Sentz DL; Rogers FA; Pan SS; Hu LT; Egorin MJ; Callery PS
    J Med Chem; 1996 Jan; 39(1):339-41. PubMed ID: 8568824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA damage in cyclophosphamide-resistant tumor cells: the role of glutathione.
    Richardson ME; Siemann DW
    Cancer Res; 1995 Apr; 55(8):1691-5. PubMed ID: 7712476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between cytotoxicity and DNA strand breakage produced by adriamycin and other intercalating agents.
    Ross WE; Zwelling LA; Kohn KW
    Int J Radiat Oncol Biol Phys; 1979 Aug; 5(8):1221-4. PubMed ID: 528266
    [No Abstract]   [Full Text] [Related]  

  • 36. Hyperbaric oxygen, whole-body X irradiation, and cyclophosphamide combination therapy in mouse leukemia L1210.
    Lottsfeldt FI; Schwartz S; Krivit W
    J Natl Cancer Inst; 1966 Jan; 36(1):37-43. PubMed ID: 5901526
    [No Abstract]   [Full Text] [Related]  

  • 37. Induction of limited DNA damage by the antitumor agent Cain's acridine.
    Furlong NB; Sato J; Brown T; Chavez F; Hurlbert RB
    Cancer Res; 1978 May; 38(5):1329-35. PubMed ID: 25133
    [No Abstract]   [Full Text] [Related]  

  • 38. Flow microfluorometric analysis of the cell cycle phase cytotoxicity of ARA-C.
    Hromas RA; Markel DE; Scholes VE
    Res Commun Chem Pathol Pharmacol; 1980 Nov; 30(2):365-8. PubMed ID: 7444164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental evaluation of potential anticancer agents XV. On the relative rates of growth and host kill of "single" leukemia cells that survive in vivo cytoxan therapy.
    Wilcox WS; Schabel FM; Skipper HE
    Cancer Res; 1966 May; 26(5):1009-14. PubMed ID: 5934786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.